Ac Immune Sa · NASDAQ:ACIU
Ac Immune Sa — Shareholder Meeting (June 2024)
39 slides from Ac Immune Sa's shareholder meeting presentation, Jun 20, 2024
Slide 1: Investor Update – Annual General Meeting June 20, 2024
NASDAQ: ACIU | AGM Presentation, June 2024 © 2024 AC Immune. Not to be used or reproduced without permission Investor Update NASDAQ: ACIU | Annual General Meeting – June 20, 2024 PIONEERING PRECISION MEDICINE TARGETED THERAPEUTICS FOR NEURODEGENERATIVE DISEASES Exhibit 99.1
Slide 2: Disclaimer
NASDAQ: ACIU | AGM Presentation, June 2024 © 2024 AC Immune. Not to be used or reproduced without permission Disclaimer This presentation contains statements that constitute “forward - looking statements” within the meaning of Section 27 A of the Securities Act of 1933 and Section 21 E of the Securi
Slide 3: Agenda
NASDAQ: ACIU | AGM Presentation, June 2024 © 2024 AC Immune. Not to be used or reproduced without permission 3 Agenda AC Immune’s approach to neurodegenerative diseases 1. Business strategy and pipeline update 2. Clinical - stage active immunotherapy programs 3. Achievements and key milestones 2023/
Slide 4: AC Immune's approach to neurodegenerative diseases
1. AC Immune’s approach to neurodegenerative diseases
Slide 5: AC Immune at a glance
NASDAQ: ACIU | AGM Presentation, June 2024 © 2024 AC Immune. Not to be used or reproduced without permission AC Immune at a glance Pioneering new ways to treat neurodegenerative diseases 5 (1) As of March 31, 2024; excluding treasury shares; (2) as of March 31, 2024; (3) assumes second ACI - 35 - re
Slide 6: Business strategy and pipeline update
2. Business strategy and pipeline update
Slide 7: Broad and robust pipeline in neurodegenerative diseases
NASDAQ: ACIU | AGM Presentation, June 2024 © 2024 AC Immune. Not to be used or reproduced without permission Partner News PHASE 3 PHASE 2 PHASE 1 Preclinical Lead Discovery INDICATION PRODUCT CANDIDATE CLASS Q3 ‘24 Updated guidance on reporting AD 1 treatment ACI - 24.060 (anti - Abeta) Active Immun
Slide 8: Technology platforms driving validating pharma deals
NASDAQ: ACIU | AGM Presentation, June 2024 © 2024 AC Immune. Not to be used or reproduced without permission AC Immune technology platforms driving validating pharma deals Strategy: optimize value to risk ratio and retain significant upside 8 ■ Considerable additional potential value in our unpartne
Slide 9: Clinical-stage active immunotherapy programs
3. Clinical - stage active immunotherapy programs
Slide 10: Active immunotherapy advantages in neurodegenerative diseases
targeting neurodegenerative diseases Long - lasting specific immunity for pathological target, consistent, boostable, durable Limited annual dosing (once or twice) after priming year No observed ARIA - E 1 to date (safety profile well suited to long - term use) Cost - effective (attractive healthcar
Slide 11: ACI-24.060: Anti-Abeta for Alzheimer's disease
ACI - 24.060: Anti - Abeta for Alzheimer’s disease
Slide 12: Landmark deal for ACI-24.060 in Alzheimer's disease
NASDAQ: ACIU | AGM Presentation, June 2024 © 2024 AC Immune. Not to be used or reproduced without permission Landmark deal for ACI - 24.060 in Alzheimer’s disease 12 Supports promise of active immunization for neurodegenerative diseases ■ The deal with Takeda covers AC Immune’s unique, class - leadi
Slide 13: Biomarker-based Phase 1b/2 study of ACI-24.060 in AD and DS
NASDAQ: ACIU | AGM Presentation, June 2024 © 2024 AC Immune. Not to be used or reproduced without permission Treatment in AD 4 (up to 4 dose/regimen cohorts) (12 months) 13 : Biomarker - based Phase 1b/2 study of ACI - 24.060 in AD 1 and DS 2 Placebo - controlled Phase 1b/2 Study Overview Trial Sche
Slide 14: Active immunotherapy: a new class of treatment
NASDAQ: ACIU | AGM Presentation, June 2024 © 2024 AC Immune. Not to be used or reproduced without permission 14 Active immunotherapy: a new class of treatment for neurodegenerative diseases Potential for profound social and economic impact Treatment Maintenance Prevention for global treatment and pr
Slide 15: Achievements and key milestones 2023/24
4. Achievements and key milestones 2023/24
Slide 16: 2023 highlights: a year of consolidation
NASDAQ: ACIU | AGM Presentation, June 2024 © 2024 AC Immune. Not to be used or reproduced without permission AC Immune 2023 highlights A year of consolidation for clinical programs ▪ Wholly - owned assets advanced towards clinical development ▪ Started IND 1 - enabling studies for mAb TDP - 43 (ALS
Slide 17: Key milestones in 2024
NASDAQ: ACIU | AGM Presentation, June 2024 © 2024 AC Immune. Not to be used or reproduced without permission H2 H1 Active immunotherapies Updated guidance on reporting ABATE interim results Abeta ACI - 24.060 (Takeda) ABATE: Interim DS 3 data on safety and immunogenicity First Patient In Phase 2b cl
Slide 18: Financial figures
5. Financial figures
Slide 19: 2023 Financial Overview
NASDAQ: ACIU | AGM Presentation, June 2023 © 2023 AC Immune. Not to be used or reproduced without permission 2023 Financial Overview 19 Key financial data (IFRS) Change 2022 2023 For the year ended December 31, (in CHF million) (except per share data) 10.9 3.9 14.8 Revenues 5.7 (60.3) (54.6) R&D exp
Slide 20: AC Immune financial position
NASDAQ: ACIU | AGM Presentation, June 2024 © 2024 AC Immune. Not to be used or reproduced without permission AC Immune financial position 20 Value - driven cash management (1) As of March 31, 2024; (2) Assumes second ACI - 35.030 milestone payment of CHF 25m received in 2025, no other milestones or
Slide 21: Strong track record in deals with leading pharma companies
NASDAQ: ACIU | AGM Presentation, June 2024 © 2024 AC Immune. Not to be used or reproduced without permission AC Immune strong track record in deals 1 with leading pharma companies Strategy: optimize value to risk ratio and retain significant upside 21 (1) Disclosure limited due to confidentiality ag
Slide 22: Technology platforms driving validating pharma deals
NASDAQ: ACIU | AGM Presentation, June 2024 © 2024 AC Immune. Not to be used or reproduced without permission AC Immune technology platforms driving validating pharma deals Strategy: optimize value to risk ratio and retain significant upside 22 ■ An integrated approach to Central Nervous System (CNS)
Slide 23: Summary and Strategic outlook
6. Summary and Strategic outlook
Slide 24: Creating the future of Precision Medicine in neurodegeneration
NASDAQ: ACIU | AGM Presentation, June 2024 © 2024 AC Immune. Not to be used or reproduced without permission Creating the future of Precision Medicine in neurodegeneration The foundation for early detection and treatment 24 3 - year cash runway permits achievement of key milestones & execution of va
Slide 25: Shifting the treatment paradigm towards precision medicine and prevention
NASDAQ: ACIU | AGM Presentation, June 2024 © 2024 AC Immune. Not to be used or reproduced without permission 25 Shifting the treatment paradigm for neurodegenerative disease towards precision medicine and disease prevention AC Immune: Pioneering science and precision medicine
Slide 26: Agenda items and proposals of the Board of Directors
Agenda items and proposals of the Board of Directors
Slide 27: Approval of 2023 IFRS and Statutory Financial Statements
NASDAQ: ACIU | AGM Presentation, June 2024 © 2024 AC Immune. Not to be used or reproduced without permission Agenda item 1 2023 IFRS Consolidated Financial Statements, 2023 Statutory Financial Statements and 2023 Compensation Report 27 1.1 Approval of 2023 IFRS Consolidated Financial Statements and
Slide 28: Advisory vote on the 2023 Compensation Report
NASDAQ: ACIU | AGM Presentation, June 2024 © 2024 AC Immune. Not to be used or reproduced without permission Agenda item 1 2023 IFRS Consolidated Financial Statements, 2023 Statutory Financial Statements and 2023 Compensation Report 28 1.2 Advisory vote on the 2023 Compensation Report ■ The Board of
Slide 29: Appropriation of Losses
NASDAQ: ACIU | AGM Presentation, June 2024 © 2024 AC Immune. Not to be used or reproduced without permission Agenda item 2 Appropriation of Losses 29 ■ The Board of Directors proposes the following appropriation of losses: In CHF K (262,115) Accumulated profit (loss) at Jan 1, 2023 (48,883) Net prof
Slide 30: Discharge of the Board and Executive Committee
NASDAQ: ACIU | AGM Presentation, June 2024 © 2024 AC Immune. Not to be used or reproduced without permission Agenda item 3 Discharge of the Members of the Board of Directors and the Executive Committee 30 ■ The Board of Directors proposes that all Members of the Board of Directors and the Executive
Slide 31: Board of Directors compensation vote
NASDAQ: ACIU | AGM Presentation, June 2024 © 2024 AC Immune. Not to be used or reproduced without permission Agenda item 4 Compensation for the Members of the Board of Directors and the Executive Committee 31 4.1 Binding vote on Maximum Aggregate Compensation for Members of the Board of Directors fr
Slide 32: Executive Committee compensation vote
NASDAQ: ACIU | AGM Presentation, June 2024 © 2024 AC Immune. Not to be used or reproduced without permission Agenda item 4 Compensation for the Members of the Board of Directors and the Executive Committee 32 4.2 Binding vote on Maximum Aggregate Compensation for Members of the Executive Committee f
Slide 33: Re-election of Members of the Board of Directors
NASDAQ: ACIU | AGM Presentation, June 2024 © 2024 AC Immune. Not to be used or reproduced without permission Agenda item 5 Re - elections 33 5.1 Re - election of Members of the Board of Directors ■ The Board of Directors proposes that each of the following persons be re - elected for a term of offic
Slide 34: Re-election of Compensation, Nomination and Governance Committee
NASDAQ: ACIU | AGM Presentation, June 2024 © 2024 AC Immune. Not to be used or reproduced without permission Agenda item 5 Re - elections 34 5.2 Re - election of Members of the Compensation, Nomination and Corporate Governance Committee ■ The Board of Directors proposes that: ■ Monika Bütler ■ Roy T
Slide 35: Re-election of the Statutory Auditors
NASDAQ: ACIU | AGM Presentation, June 2024 © 2024 AC Immune. Not to be used or reproduced without permission Agenda item 5 Re - elections 35 5.3 Re - election of the Statutory Auditors ■ The Board of Directors proposes that PricewaterhouseCoopers SA, in Pully, Switzerland, be re - elected as Statuto
Slide 36: Re-election of the Independent Proxy
NASDAQ: ACIU | AGM Presentation, June 2024 © 2024 AC Immune. Not to be used or reproduced without permission Agenda item 5 Re - elections 36 5.4 Re - election of the Independent Proxy ■ The Board of Directors proposes that Reymond & Associés , Lausanne, be re - elected as Independent Proxy for a ter
Slide 37: Changes in the Articles of Association
NASDAQ: ACIU | AGM Presentation, June 2024 © 2024 AC Immune. Not to be used or reproduced without permission Agenda item 6 Changes in the Articles of Association 37 ■ The Board of Directors has withdrawn its proposals for agenda items 6.1, 6.2, and 6.3. ■ The Board of Directors therefore now submits
Slide 38: Changes in the Articles of Association: Other changes
NASDAQ: ACIU | AGM Presentation, June 2024 © 2024 AC Immune. Not to be used or reproduced without permission Agenda item 6 Changes in the Articles of Association 38 6.4 Other changes ■ The Board of Directors proposes to change the following Articles as reflected in Annex 1 to the AGM 2024 Invitation
Slide 39: Thank you for your attendance and support
NASDAQ: ACIU | AGM Presentation, June 2024 © 2024 AC Immune. Not to be used or reproduced without permission 39 We thank y ou for your attendance and your continued support.